The MND Unit of the Hospital Universitari i Politècnic La Fe is the referral centre in the Valencian region and one of the referral centres in Spain for MND patients. We are also part of the European Research Network for rare neuromuscular diseases. Our research group is integrated in the Research Group of Neuromuscular Pathology and Ataxias (GIPNMA) and is part of the Spanish network for research in rare diseases (CIBERER). Our main research interests are the phenotypic and genetic characterization of our patient cohort, the search of biomarkers and clinical trials.
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).